Abstract
Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects. Among secondary osteoporosis, glucocorticoidinduced osteoporosis is the most common and severe form, and up to now prolonged glucocorticoid therapy has been considered the most important osteoporotic risk factor in rheumatic patients. However, it is now clear that the pathogenesis of osteoporosis in inflammatory rheumatic diseases is mediated by several factors. In particular, new discoveries within osteoimmunology concerning the complex relationship between bone and immunity, suggest that inflammation itself, through proinflammatory and osteoclastogenic cytokine overexpression, promotes bone resorption leading to increased skeletal fragility. Therefore, by controlling systemic inflammation, it is also possible to reduce the loss of bone mass which accompanies rheumatic diseases. From this point of view, we critically revisit the effects of glucocorticoids on bone in rheumatic diseases, in which they should be seen not just as an enemy of the bone health but eventually as a potential therapeutic tool capable of reducing the risk of osteoporosis by controlling disease activity and inflammation.
Keywords: Bone, glucocorticoid, inflammation, osteoporosis, rheumatic diseases, translational medicine.
Current Medicinal Chemistry
Title:Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?
Volume: 22 Issue: 5
Author(s): Fedra Ciccarelli, Massimo De Martinis and Lia Ginaldi
Affiliation:
Keywords: Bone, glucocorticoid, inflammation, osteoporosis, rheumatic diseases, translational medicine.
Abstract: Increased bone resorption and enhanced risk of osteoporotic fractures are often reported in patients with diseases having immune system involvement, mainly inflammatory rheumatic diseases, for which glucocorticoids are more often prescribed because of their powerful antinflammatory effects. Among secondary osteoporosis, glucocorticoidinduced osteoporosis is the most common and severe form, and up to now prolonged glucocorticoid therapy has been considered the most important osteoporotic risk factor in rheumatic patients. However, it is now clear that the pathogenesis of osteoporosis in inflammatory rheumatic diseases is mediated by several factors. In particular, new discoveries within osteoimmunology concerning the complex relationship between bone and immunity, suggest that inflammation itself, through proinflammatory and osteoclastogenic cytokine overexpression, promotes bone resorption leading to increased skeletal fragility. Therefore, by controlling systemic inflammation, it is also possible to reduce the loss of bone mass which accompanies rheumatic diseases. From this point of view, we critically revisit the effects of glucocorticoids on bone in rheumatic diseases, in which they should be seen not just as an enemy of the bone health but eventually as a potential therapeutic tool capable of reducing the risk of osteoporosis by controlling disease activity and inflammation.
Export Options
About this article
Cite this article as:
Ciccarelli Fedra, Martinis De Massimo and Ginaldi Lia, Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?, Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867321666141106125051
DOI https://dx.doi.org/10.2174/0929867321666141106125051 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokines in Gastrointestinal Disorders
Current Drug Targets The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Use of Nanotechnology in Diagnosis and Treatment of Hepatic Fibrosis: A Review
Current Drug Delivery Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Gene Therapy for Gastric Diseases
Current Gene Therapy An Updated Patent Review on Ocular Drug Delivery Systems with Potential for Commercial Viability
Recent Patents on Drug Delivery & Formulation Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Oxidative Stress in Allergic and Inflammatory Skin Diseases
Current Drug Targets - Inflammation & Allergy Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Ganglioside Mimicry as a Cause of Guillain-Barre Syndrome
CNS & Neurological Disorders - Drug Targets B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation
Current Chemical Biology Mechano-Regulation of Alternative Splicing
Current Genomics Thiazolides, a Novel Class of Anti-Infective Drugs, Effective Against Viruses, Bacteria, Intracellular and Extracellular Protozoan Parasites and Proliferating Mammalian Cells
Anti-Infective Agents Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry Editorial [Hot Topic: Fracture Risk Associated with Prescribed Medication (Guest Editor: Peter Vestergaard) ]
Current Drug Safety Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer Cells
Current Drug Targets - Immune, Endocrine & Metabolic Disorders